Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.91 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.91 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.91 |
| ▸ | MAPT | P10636 | 1/20 | 0.80 |
| ▸ | FABP3 | P05413 | 1/20 | 0.71 |
| ▸ | RECQL | P46063 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.62 |
| ▸ | PTAFR | P25105 | 1/20 | 0.62 |
| ▸ | HTR1D | P28221 | 1/20 | 0.62 |
| ▸ | HTR2C | P28335 | 1/20 | 0.62 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.62 |
| ▸ | DRD3 | P35462 | 1/20 | 0.62 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.62 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.56 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.56 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.56 |
| ▸ | PRKCG | P05129 | 1/20 | 0.56 |
| ▸ | PRKCB | P05771 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL417649 | 0.97 | SMN1; SMN2 (0.98) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL10498112 | 0.95 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| Dimyristoylphosphatidylcholine SCHEMBL244839 | 0.95 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL2036043 | 0.95 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL24563 | 0.95 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| Dimyristoylphosphatidylcholine SCHEMBL236969 | 0.95 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL233046 | 0.95 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL231824 | 0.95 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL22693933 | 0.95 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| Dimyristoylphosphatidylcholine SCHEMBL37475 | 0.95 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398940-A1 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | CureVac SE (DE) | 2024-12-05 | — | — | US | claimed |
| EP-4395820-A2 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS COMPRISING PHOSPHATIDYLSERINE | CureVac SE (DE) | 2024-07-10 | — | — | EP | claimed |
| EP-4395748-A1 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | CureVac SE (DE) | 2024-07-10 | — | — | EP | claimed |
| US-20230090515-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | CUREVAC AG (DE) | 2023-03-23 | — | — | US | claimed |
| WO-2023031394-A1 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | CureVac SE (DE) | 2023-03-09 | — | — | WO | claimed |
| WO-2023031392-A2 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS COMPRISING PHOSPHATIDYLSERINE | CureVac SE (DE) | 2023-03-09 | — | — | WO | claimed |
| US-20220354963-A1 | EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF | CODIAK BIOSCIENCES, INC. (US) | 2022-11-10 | — | — | US | claimed |
| EP-4076647-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | CureVac AG (DE) | 2022-10-26 | — | — | EP | claimed |
| US-20200376138-A1 | LIPID NANO PARTICLE COMPLEX COMPRISING APTIDE FUSED WITH CELL PENETRATING MATERIALS AND USE SAME | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-12-03 | — | — | US | claimed |
| WO-2020241925-A1 | LIPID NANOPARTICLE COMPLEX CAPTURING APTIDE FUSED WITH CELL-PENETRATING MATERIAL AND USE THEREOF | 한국과학기술원 | 2020-12-03 | — | — | WO | claimed |
| CN-111065423-A | Liposome formulations for joint lubrication | 莫比斯医疗有限公司 | 2020-04-24 | — | — | CN | claimed |
| US-12589078-B2 | Lipid nanoparticles for delivery of nucleic acids | CureVac SE (DE) | 2026-03-31 | — | — | US | disclosed |
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | LONZA SALES AG (CH) | 2026-01-29 | — | — | US | disclosed |
| EP-4676446-A1 | NOVEL LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | CureVac SE (DE) | 2026-01-14 | — | — | EP | disclosed |
| US-20250255985-A1 | PARVOVIRUS ITR-BASED GENE DELIVERY VECTOR SYSTEM | MODEX THERAPEUTICS, INC. | 2025-08-14 | — | — | US | disclosed |
| US-20100311844-A1 | Spontaneously Forming Ellipsoidal Phospholipid Unilamellar Vesicles | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-12-09 | — | — | US | disclosed |
| WO-2010053489-A1 | FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS AND PEPTIDES FOR APPLICATION TO TRANSMEMBRANE DRUG DELIVERY SYSTEMS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2010-05-14 | — | — | WO | disclosed |
| EP-2081552-A2 | SPONTANEOUSLY FORMING ELLIPSOIDAL PHOSPHOLIPID UNILAMELLAR VESICLES | Children's Hospital Medical Center (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20090142267-A1 | FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS AND PEPTIDES FOR APPLICATION TO TANSMEMBRANE DRUG DELIVERY SYSTEMS | CHILDREN'S HOSPITAL MEDICAL CENTER | 2009-06-04 | — | — | US | disclosed |
| WO-2008051818-A2 | SPONTANEOUSLY FORMING ELLIPSOIDAL PHOSPHOLIPID UNILAMELLAR VESICLES | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | CEBPZ, OSBP, DIS3 | SMN1; SMN2 1119/4885NR5A2 1807/4885NR5A1 1445/4885 |
| US-20230090515-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | LIPA, NPC1, NPC1L1 | SMN1; SMN2 2691/4885NR5A2 3804/4885NR5A1 4062/4885 |
| US-20220354963-A1 | EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF | EXOSC5, EXOSC4, EXOSC10 | SMN1; SMN2 1847/4885NR5A2 4354/4885NR5A1 4277/4885 |
| US-12589078-B2 | Lipid nanoparticles for delivery of nucleic acids | STARD3, PCTP, EXOSC10 | SMN1; SMN2 2059/4885NR5A2 1289/4885NR5A1 344/4885 |
| US-20240398940-A1 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | ABHD16A, FASN, PHAX | SMN1; SMN2 2758/4885NR5A2 3252/4885NR5A1 3492/4885 |
| US-20250255985-A1 | PARVOVIRUS ITR-BASED GENE DELIVERY VECTOR SYSTEM | GPR68, LARP7, INCENP | SMN1; SMN2 958/4885NR5A2 1485/4885NR5A1 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.